In Vivo Testing of a Novel Blood Pump for Short-Term Extracorporeal Life Support

Nicholas R. Teman, MD, David S. Demos, MD, Benjamin S. Bryner, MD, Bradley Faliks, BS, Emilia M. Jahangir, ME, Daniel E. Mazur, BS, Alvaro Rojas-Pena, MD, Robert H. Bartlett, MD, and Jonathan W. Haft, MD

Department of Surgery, University of Michigan Health System, Extracorporeal Life Support Laboratory; Michigan Critical Care Consultants, Inc; Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, Michigan

Background. Centrifugal pumps are used increasingly for temporary mechanical support for the treatment of cardiogenic shock. However, centrifugal pumps can generate excessive negative pressure and are afterload sensitive. A previously developed modified roller pump mitigates these limitations both in vitro and in preliminary animal experiments. We report the results of intermediate-term testing of our evolving pump technology, known as the BioVAD.

Methods. The BioVAD was implanted in 6 adult male sheep (62.5 ± 3.9 kg), with drainage from the left atrium and reinfusion into the descending aorta. The sheep were monitored for 5 days. Heparin was given during the initial implantation, but no additional anticoagulants were given. Data collected included hemodynamic status, pump flow and pressures, laboratory values to monitor end-organ function and hemolysis, pathologic specimens to evaluate for thromboembolic events and organ ischemia, and explanted pump evaluation results.

Results. All animals survived the planned experimental duration and there were no pump malfunctions. Mean BioVAD flow was 3.57 ± 0.30 L/min (57.1 mL/kg/min) and mean inlet pressure was –30.51 ± 4.25 mm Hg. Laboratory values, including plasma free hemoglobin, creatinine, lactate, and bilirubin levels, remained normal. Three animals had small renal cortical infarcts, but there were no additional thromboembolic events or other abnormalities seen on pathologic examination. No thrombus was identified in the BioVAD blood flow path.

Conclusions. The BioVAD performed well for 5 days in this animal model of temporary left ventricular assistance. Its potential advantages over centrifugal pumps may make it applicable for short-term mechanical circulatory support.

© 2014 by The Society of Thoracic Surgeons

Temporary cardiac support devices have become an important tool in the treatment of refractory cardiogenic shock. A variety of blood pumps have been used in this application, including roller, pneumatic, and now increasingly centrifugal designs. Although generally safe, there are several disadvantages to centrifugal pumps. These pumps operate at a fixed rotational speed, requiring manual adjustments to accommodate the rapid fluctuations in intravascular volume status that can be seen in critically ill patients. They are sensitive to variations in afterload, resulting in potentially undesired changes in flow [1]. There is also the concern for cavitation and hemolysis resulting from excessive negative pressure [2]. In addition, rotary blood pumps are associated with acquired von Willebrand’s factor deficiency and may contribute to bleeding complications [3–7].

A nonocclusive peristaltic-type pump—the BioVAD (Michigan Critical Care Consultants, Ann Arbor, MI) has been developed that has the potential to mitigate the possible disadvantages of centrifugal pumps. Our group previously studied this device in vitro, demonstrating its intrinsic volume responsiveness, afterload insensitivity, and avoidance of excessive negative suction [8]. The BioVAD was also tested in a 4-hour in vivo sheep model and was found to have a favorable hemodynamic profile in the support of these animals [9]. The objective of this study was to determine the performance and safety of the BioVAD pump in a 5-day sheep model and to evaluate the effect of the pump on hemolysis, end-organ function, and thrombosis.

Material and Methods

Study Design

All animals received humane care in compliance with the 1996 Guide for the Care and Use of Laboratory Animals and the US National Institutes of Health. The University of Michigan Committee on the Use and Care of Animals, Drs Bartlett, Jahangir and Mazur disclose financial relationships with MC3 Corporation.

Address correspondence to Dr Haft, Department of Cardiac Surgery, University of Michigan Health System, 1500 E Medical Center Dr, SPC 5864, Ann Arbor, MI 48109; e-mail: haft@med.umich.edu.

Accepted for publication April 1, 2014.

© 2014 by The Society of Thoracic Surgeons

Published by Elsevier Inc

http://dx.doi.org/10.1016/j.athoracsur.2014.04.027
protocol number 0004117, approved all experiments. The BioVAD device was implanted in 6 adult male sheep (62.5 ± 3.9 kg). Animals were supported for 5 days, during which routine vital signs, pump measurements, and laboratory test results were recorded. At the end of the experiments, the animals were euthanized and necropsy was performed along with evaluation of the pump.

BioVAD Design

The BioVAD device is shown in Fig 1 and can be modified for different sizes and flow demands. Details of the BioVAD pump have been published previously [10]. Briefly, it consists of a collapsible polyurethane chamber stretched around 3 rollers and maintained in a sealed housing. Suction can be applied to the housing to generate vacuum-assisted drainage. A schematic of the pump chamber at different degrees of venous return is shown in Fig 2. The pump head is disposable and designed for a single use. It sits on a motor plate that is magnetically driven to a maximum speed of 150 rpm. For this animal model, the chosen pump chamber has a maximum volume of 65 mL and a maximum stroke volume of 55.5 mL per revolution. The pump is controlled by a console that displays the pump speed (in revolutions per minute), amount of suction generated (in millimeters of mercury), and the percent fill of the pump chamber (Fig 3). The console has a connection port for a 3/8-inch flow probe, and the amount of flow is shown on the console display.

Surgical Technique

Propofol (5 mg/kg) was used for anesthetic induction, and isoflurane (1%–5%) was used for anesthetic maintenance. An arterial line was placed in the carotid artery, and a sheath introducer and pulmonary artery catheter were placed through the jugular vein. A left thoracotomy was performed and the pericardium was opened. Heparin was administered (100 IU/kg), and activated clotting times were measured, with a goal greater than 300 seconds. After this initial heparinization, no further anticoagulant was administered during the operation or the postoperative course. A 10-mm woven polyester graft bonded to 3/8-inch tubing was anastomosed to the descending aorta in an end-to-side fashion. A 28F right-angle cannula (Medtronic DLP; Medtronic, Minneapolis, MN) was inserted into the left atrium and secured with double purse-string sutures. The cannula and graft were tunneled out of the chest. The chest was closed with a 32F thoracostomy tube in place. The pump and circuit were primed with 1 L of lactated Ringer’s solution mixed with 50 mL of 8.4% sodium bicarbonate. The cannula and graft were connected to the BioVAD device using standard barbed connectors and 3/8-inch polyvinyl chloride tubing.

Postoperative Care and Data Collection

The animals were extubated within hours after the operation. The pump was maintained at a constant setting, with speed of 80 rpm and ~60 mm Hg of vacuum, settings that in previous in vivo studies produced a flow rate of approximately 60 mL/kg/min. No adjustments were made to the pump settings in the postoperative period. Laboratory personnel observed the sheep for the entirety of the experiment for the purpose of collecting data, providing pain control, and ensuring the safety of the animals. Postoperative analgesia was achieved with buprenorphine (0.005–0.01 mg/kg), flunixin (2 mg/kg), and transdermal fentanyl (100 μg). Perioperative antibiotic administration was maintained for 24 hours after operation (cefazolin 1 g). Continuous monitoring of heart rate, systemic blood pressure, central venous pressure, and pulmonary artery pressure was performed (Solar 8000, GE Marquette Medical Systems, Milwaukee, Wisconsin). Pump inlet and outlet pressures were measured from luer ports in the circuit immediately proximal and distal to the BioVAD device. Baseline laboratory test were performed, including complete blood count, comprehensive metabolic panel (including renal and liver function), coagulation panel, and plasma free hemoglobin, and were repeated daily. Arterial blood gas measurements were obtained to assess readiness for extubation and on an as-needed basis to assist with acid-base and electrolyte management. After necropsy, organs including lungs, heart, kidneys, spleen, and liver were submitted for gross and microscopic pathologic examination. The pump chambers were drained of blood and inspected for clot or signs of fatigue.

Analysis of variance (ANOVA) was performed to compare the means of the laboratory values for each day. Statistical analysis was performed using Stata, version 12 (StataCorp LP, College Station, TX). Statistical significance was defined as a p value less than 0.05.

Results

The BioVAD device was implanted successfully and without complication in each of the 6 animals. All animals survived 4 to 5 days without event (1 animal was euthanized after 4 days for logistic reasons). There were no pump malfunctions and no setting manipulations throughout the duration of each experiment, with vacuum at ~60 mm Hg and pump speed set at 80 rpm. Mean pump flow remained stable and is shown in Fig 4. The
Overall mean flow was 3.57 ± 0.30 L/min (57.1 mL/kg/min). Mean inlet pressure was –30.51 ± 4.25 mm Hg and was stable over the duration of support (Fig 5). Mean pulse pressure at baseline was 29.5 ± 4.1 mm Hg and decreased to 19.7 ± 3.4 mm Hg after initiation of support.

Table 1 shows the mean laboratory values for each day of the experiments. There was a slight increase in plasma free hemoglobin levels in the 2 days after implantation, which remained much lower than clinically significant levels of hemolysis and returned to baseline levels soon after this. Likewise, platelet counts decreased in the 2 days after implantation but returned to baseline levels by day 4. ANOVA showed significant variation in levels of plasma free hemoglobin, creatinine, and lactic acid, with the latter 2 levels decreasing from baseline.

After necropsy of the animal, the heart, lungs, liver, kidneys, and spleen were sent for gross and microscopic pathologic evaluation. There was no evidence of gross intestinal infarction. Three of the animals had small renal cortical infarctions, which appeared to be embolic in origin. There were no other signs of thromboembolism. The remaining 3 animals were free of any pathologic abnormalities.

The circuit and pump were inspected for thrombus formation or chamber disruption or fatigue. Selected photographs are shown in Fig 6. There was no evidence of thrombus formation in the pump chamber or the tubing from the pump to the animal. There was ring thrombus noted at the transition points of connectors in the circuit, as is typically seen in any prolonged use of an extracorporeal circuit.
Comment

The use of durable ventricular assist devices (VADs) for patients with cardiac failure as a bridge to transplantation or as destination therapy is increasing, with acceptable short- and long-term survival [11–13]. However, these devices are expensive and require specialized teams and protocols for implementation and long-term management. They are primarily used at tertiary care centers and are rarely implanted in patients with critical cardiogenic shock [14]. Temporary mechanical circulatory support with simpler and less expensive systems allows resuscitation of end organs and provides time to select the most appropriate candidates for durable VAD implantation [15]. This strategy may prevent overuse of durable VADs, either in unsalvageable patients or in those in whom significant cardiac recovery is possible. Furthermore, initiation of temporary mechanical support at community hospitals may stabilize critically ill patients who have undergone shock before transfer to larger centers and prevent additional and potentially irreversible end-organ injury [16, 17].

Several types of blood pumps have been used for temporary mechanical circulatory support [18–25]. These include pneumatic systems such as the Abiomed BVS 5000 and the AB5000 (Abiomed, Inc, Danvers, MA). These pumps automatically adjust flow based on intravascular volume and avoid excessive negative pressure by precisely regulating vacuum applied to the filling chambers. However, the inflow and outflow valves result in zones of blood stagnation, which can lead to thrombus formation and thromboembolic complications. Microaxial blood pumps like the Impella 2.5 and 5.0 (Abiomed, Inc) require placement across the semilunar valves using either fluoroscopy or echocardiography [26]. These devices can easily become malpositioned, leading to inadequate support or hemolysis from impingement on the inflow or outflow blood flow paths [27]. In addition, they can cause valvular injury during placement or removal [28]. Centrifugal pumps, such as the CentriMag (Thoratec, Inc, Pleasanton, CA) and the TandemHeart (Cardiac Assist, Inc, Pittsburgh, PA) can be used as short-term VADs, either surgically or percutaneously, or can be used for extracorporeal membrane oxygenation (ECMO). Centrifugal pumps operate at a fixed rotational speed and

Table 1. Mean Laboratory Values for 6 Sheep Supported on the BioVAD Circulatory Support Device

<table>
<thead>
<tr>
<th>Laboratory Value</th>
<th>Baseline</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
<th>Day 5</th>
<th>p Value^a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma free hemoglobin (mg/dL)^b</td>
<td>2.1 ± 1.6</td>
<td>4.4 ± 4.1</td>
<td>3.5 ± 2.7</td>
<td>2.4 ± 1.8</td>
<td>2.6 ± 1.9</td>
<td>1.2 ± 0.4</td>
<td>0.002</td>
</tr>
<tr>
<td>Platelets (K/mm^3)^c</td>
<td>223 ± 143</td>
<td>142 ± 85</td>
<td>108 ± 64</td>
<td>128 ± 72</td>
<td>182 ± 179</td>
<td>232 ± 245</td>
<td>0.05</td>
</tr>
<tr>
<td>Lactic acid (mmol/L)^d</td>
<td>1.8 ± 0.9</td>
<td>1.2 ± 0.8</td>
<td>0.7 ± 0.3</td>
<td>0.5 ± 0.2</td>
<td>0.5 ± 0.2</td>
<td>0.5 ± 0.3</td>
<td>0.002</td>
</tr>
<tr>
<td>Creatinine (mg/dL)^e</td>
<td>1.0 ± 0.2</td>
<td>1.0 ± 0.3</td>
<td>0.9 ± 0.6</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)^f</td>
<td>0.1 ± 0.08</td>
<td>0.3 ± 0.16</td>
<td>0.2 ± 0.15</td>
<td>0.2 ± 0.11</td>
<td>0.2 ± 0.08</td>
<td>0.2 ± 0.08</td>
<td>0.46</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)^g</td>
<td>7.2 ± 0.7</td>
<td>6.9 ± 1.1</td>
<td>6.6 ± 0.7</td>
<td>6.7 ± 0.7</td>
<td>6.7 ± 0.8</td>
<td>6.3 ± 0.8</td>
<td>0.91</td>
</tr>
</tbody>
</table>

^a p value determined by analysis of variance (ANOVA); reference ranges.

---

Fig 5. Inlet pressure values for 6 healthy sheep supported on the BioVAD circulatory support device.

Fig 6. Photographs of (A) BioVAD pump head and (B) tubing after necropsy.
require manual adjustments for large changes in intravascular volume status. During periods of hemodynamic stability, centrifugal pumps do not require much manipulation and appear much less thrombogenic than their pulsatile predecessors. However, during abrupt reduction in intravascular volume, suction generated by centrifugal pumps can be substantial, manifested by “chattering,” and at high speeds can result in cavitation, hemolysis, and vascular injury. In addition, ventricular unloading may be less with continuous flow pumps than with pulsatile pumps that operate in a fill-to-empty cycle [29]. This may have important implications in terms of creating the best conditions to allow myocardial recovery.

The ideal pump for short-term mechanical support should be easy to use, capable of functioning without a significant amount of manipulation, biocompatible with minimal thrombogenicity, intrinsically responsive to the patient’s fluid status, and resistant to changes in afterload. The pump should also be able to function in a left ventricular assist device, right ventricular assist device, or biventricular assist device configuration or as a component of an ECMO circuit. Priming and operation should be rapid and intuitive, facilitating use at centers that may apply the system infrequently.

The BioVAD described in this study could potentially fulfill each of these ideal qualities. The concept of the peristaltic nonocclusive roller-type pump was originally formulated to create a safe pump for cardiopulmonary bypass perfusion systems. The original pump design was unsuitable for more prolonged circulatory assistance because it has a large footprint and requires gravity for venous drainage. The BioVAD was a result of modifications to this early pump that made it more compact with a sealed housing, allowing vacuum-augmented drainage and using magnetic coupling to the motor, creating a cost-effective disposable single-use cartridge. The console provides a simple and intuitive user interface, with inputs of pump speed and vacuum strength. By reporting “percent pump chamber fill,” the bedside nurse can easily see if changes in pump speed are warranted. Alternatively, algorithms can easily be made to automatically adjust pump speed to maintain “percent fill” within a specified range. Our previous work has shown that the BioVAD pump, with these modifications, preserves the hemodynamic and safety advantages of the earlier pump [8].

In this study, 6 sheep were supported with the BioVAD pump with left atrial drainage and aortic reinfusion for 4 to 5 days without event. Pump flows and hemodynamic data remained stable throughout the experiments. There was minimal laboratory evidence of end-organ dysfunction, and there were minimal thromboembolic events. Our previous work with an animal model used cannulation of the left ventricular apex for drainage into the pump. For this series of experiments, we chose to place the drainage cannula in the left atrium because of concerns that contractility of the left ventricle artificially augmented flow through the pump. This study is also the first use of the pump for an extended period.

As stated earlier, 1 of the advantages of the BioVAD pump is fluid responsiveness. As the venous pressure increases, the pump chamber expands and a greater percentage of the maximum volume capacity of the chamber is reached. This results in an increase in the flow generated by the pump. In our experiments, the flow remained largely stable throughout the postoperative course because the sheep were previously healthy and the operations were performed efficiently with minimal blood loss. We previously demonstrated the intrinsic volume responsiveness of the BioVAD during simulated large volume shifts [8, 9].

There are several limitations to this study. In this first recovery trial of the pump, we elected to use healthy animals for our study. The pump mechanics and hemodynamic data would likely be quite different in a cardiogenic shock model. Furthermore, the true effect of the pump on the failing heart cannot be assessed in this study because the normal functioning heart may be compensating for pump deficiencies. There were also several renal thromboembolic events noted on pathologic examination after necropsy. After the initial heparin dose for graft and cannula placement, no additional anticoagulation was used. This was our first experience with a recovery model for this pump and we did not want the results to be clouded by potential bleeding complications. In addition, we wanted to determine the thrombogenicity of the device under a “worst-case scenario” in which anticoagulation was withheld. Future study will include the addition of anticoagulation as well as the use of coated surfaces to prevent thrombus formation.

The pump on cardiac function, particularly in a heart failure model.

This study demonstrates that the BioVAD pump performed well in a 5-day recovery implant model without anticoagulation. There was minimal negative pressure and hemolysis and no need for pump setting adjustments. We believe that the BioVAD pump may be ideally suited for short-term mechanical support and could potentially be used as a component of a left ventricular assist device, right ventricular assist device, or ECMO. Its simple concept and intuitive interface may be ideal for the community hospital that anticipates infrequent use of mechanical assist devices.

References
1. Salamonsen RF, Mason DG, Ayre PJ. Response of rotary blood pumps to changes in preload and afterload at a fixed

This work was supported by NIH grant No. 5R42HL096166-3. The BioVAD name and patents related to the pump are owned by Michigan Critical Care Consultants, Inc (Ann Arbor, MI). Three of the authors (EMJ, DEM, RHB) are either employees of Michigan Critical Care Consultants or equity stakeholders.
speed setting are unphysiological when compared with the natural heart. Artif Organs 2011;35:47-53.

INVITED COMMENTARY

In this issue of The Annals of Thoracic Surgery, Teman and colleagues [1] have provided an interesting report on a novel blood pump, the BioVAD, designed to be used for relatively short-term mechanical circulatory support. Their report describes the successful use of a nonocclusive peristaltic pump for 5 days of support in an adult ovine survival model. All animals were stable, and use of the pump was associated with no obvious complications except some small renal emboli. Importantly, the brains of the animals were not evaluated for similar embolic phenomena. There was biochemical evidence of metabolic stability and a low rate of hemolysis.

As the field of mechanical circulatory support continues to evolve, the technology and indications for it will continue to evolve as well. One important question will relate to the number and types of pumps that will be commercially available. Critical considerations that will factor into this question include safety and cost. Currently available